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ABSTRACT
In Libya neuropathic pain is rarely assessed in patients with diabetes. The Leeds Assessment
of Neuropathic Symptoms and Signs (LANSS) pain scale is used worldwide to screen for
neuropathic pain. There is no Arabic version of LANSS for use in Libya. The aim of this study
was to develop an Arabic version of LANSS and to assess its validity and reliability in diabetic
patients in Benghazi, Libya. LANSS was translated into Arabic by four bilingual translators and
back translated to English by a university academic. Validity and reliability of the Arabic
LANSS was assessed on 110 patients attending a Diabetes Centre in Benghazi. Concurrent
validity was tested and compared with the Self-completed Leeds Assessment of Neuropathic
Symptoms and Signs (S-LANSS). Test-retest reliability was conducted 1–2 weeks later. Internal
consistency and inter-class correlation (ICC) between LANSS and S-LANSS was also tested.
Internal consistency within first completion of the Arabic LANSS was acceptable (Cronbach’s
alpha = 0.793) and similar to the Arabic S-LANSS (0.796) and the second completion of the
Arabic LANSS (0.795). ICC between the Arabic LANSS and the Arabic S-LANSS was 0.999
(p < 0.001). Test-retest reliability (ICC) between first and second completions of the Arabic
LANSS was 0.999 (p < 0.001). Kappa measurement of agreement between the two Arabic
LANSS completions and S-LANSS was high on all seven items (Kappa >0.95, p < 0.0001). We
concluded that the Arabic version of LANSS pain scale was valid and reliable for use on Libyan
diabetic patients. This study provided results suggesting that the S-LANSS could also be used
on diabetic patients.
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1. Introduction
Screening for neuropathic pain is critical for successful
pain management and is dependent on valid and
reliable screening tools adapted for populations
from diverse ethno-cultural backgrounds [1]. Tools
used to screen for the presence of neuropathic pain
have been developed in English, French and German
for use in European countries and the USA, and
include the Leeds Assessment of Neuropathic
Symptoms and Signs (LANSS) [2], the self-reported
version of the LANSS (S-LANSS) [3], the Neuropathic
Pain Questionnaire (NPQ) [4], the Douleur
Neuropathique 4 questions (DN4) [5], painDETECT
[6], ID-Pain [7] and the Standardized Evaluation of
Pain (StEP) [8]. These tools rely on the patient’s verbal
description of the nature of their pain and may
include a simple clinical examination. Screening tools
need to be translated and culturally adapted if they
are to be used in languages other than English,
French and German.
The LANSS and S-LANSS pain scales are used glob-
ally to screen for the presence of pain of neuropathic
origin because they have high sensitivity and
specificity compared with other available tools [1].
The LANSS pain scale consists of five items that docu-
ment self-reported pain symptoms and two items that
document the findings of a simple clinical examina-
tion conducted by the healthcare professional to
assess the presence of allodynia and pin-prick thresh-
old [2]. A score of 12 or more out of 24 is used as a
cut-point to identify pain that is predominantly neu-
ropathic in origin. The S-LANSS was designed to
remove the need for clinical examination by a health
care professional by modifying the two clinical exam-
ination items so that they could be undertaken by the
patient themselves [3]. Thus, the S-LANSS can be sent
to the patient by post or completed verbally via tele-
phone conversation [3,9].
The sensitivity of the LANSS is 83% and specificity
is 87%, with an ability to identify neuropathic pain in
85% of patients with clinically confirmed diagnosis of
neuropathic pain [2]. The sensitivity and specificity of
the S-LANSS is lower than LANSS (i.e. 74% and 76%,
respectively) with an ability to identify neuropathic
pain in 75% of patients with clinically confirmed diag-
nosis of neuropathic pain [3]. Specificity and
CONTACT Osama A. Tashani O.Tashani@leedsbeckett.ac.uk Centre for Pain Research, School of Clinical and Applied Sciences, Leeds Beckett
University, City Campus, Leeds, LS1 3HE, UK
LIBYAN JOURNAL OF MEDICINE, 2017
VOL. 12, 1384288
https://doi.org/10.1080/19932820.2017.1384288
© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
sensitivity remain stable when translated versions of
the LANSS and S-LANSS are used in non-English
speaking populations including Turkish [10,11],
Spanish [12] and Chinese [13]. The LANSS pain scale
has been translated, linguistically validated and cultu-
rally adapted for use in Turkish, Dutch, Spanish,
French and Chinese populations [10,13,14]. The
S-LANSS has been translated, linguistically validated
and culturally adapted for use in Arabic populations
[9], but there is no equivalent LANSS pain scale for use
in Arabic populations.
Libya is an Arab country in the Middle East and
North Africa (MENA) region with a population of
approximately 6 million. Health care provision in
Libya is similar to other MENA countries with limited
services for the management of diabetes and chronic
pain [15]. The need to develop improved services for
the management of pain for patients with diabetes
has been recognised in policies (e.g. the Diabetes Care
Plan), but implementation has been hindered due to
war. An Arabic S-LANSS has been developed and
validated for use for the general population in Libya
[9], and was used to estimate the point prevalence of
neuropathic pain in a sample of adults experiencing
chronic pain [16]. However, the Arabic S-LANSS has
not been validated for use in populations of adults
with specific disease states.
In 2000, it was estimated that 88,000 people were
diagnosed with diabetes in Libya and that this figure
would rise to 245,000 people by 2030 [17]. In 2015,
354,000 people in Libya were diagnosed with dia-
betes indicating a far greater burden than originally
believed [18]. Painful diabetic neuropathy is a com-
mon complication of diabetes affecting up to a third
of patients [19,20] but there are no up-to-date data on
the prevalence, risk factors and treatment of painful
diabetic neuropathy in Libya. There is a need for a
culturally adapted screening tool to aid health care
professionals screen for the presence of neuropathic
pain associated with diabetes. The aim of this study
was to develop an Arabic version of the LANSS pain
scale and to assess its linguistic validity and reliability
on patients with diabetes in Benghazi, Libya. In addi-
tion, anthropometric data, clinical profiles, co-morbid-
ities and complications were collected to better
describe the sample.
2. Methods
2.1. Translation of the LANSS to Arabic
This study involved translation of the LANSS from
English to Arabic. Participants with diabetes com-
pleted the Arabic LANSS on two occasions with a
week interval, and also completed the Arabic S-
LANSS on one occasion. Data gathered was used to
test the validity, reliability and cultural
appropriateness for use in Libya. Permission to con-
duct the study was obtained from the Benghazi
Diabetes Centre and ethics approval was obtained
from the Research Ethics Committee at Leeds
Beckett University.
The translation process followed the Principles of
Good Practice for the Translation and Cultural
Adaptation Process for Patient-Reported Outcome
Measures [21] using the following steps:
(1) Preparation: Four bilingual translators who
were fluent in Arabic and English were
selected. Three translators were clinicians and
one translator was a university academic.
(2) Forward translation: the LANSS was given to all
translators to translate into Arabic.
(3) Reconciliation: The four translated documents
were shared between all translators and discre-
pancies, ambiguities and issues arising were dis-
cussed and resolved by consensus. A final draft
Arabic version of the LANSS was produced.
(4) Backward translation and review: The final draft
Arabic version of the LANSS was translated back
into English by a translator who had not been
involved in forward translation and who was
blind to the original English version of the
LANSS.
(5) Harmonization, cognitive debriefing and
reviewing of results: The back-translated
English version of the LANSS was compared
with the original LANSS and discrepancies,
ambiguities and typographic and/or grammati-
cal errors discussed within the group and a
final draft of the Arabic version.
(6) Proof reading and final report: The authenticity
of the translation was agreed by consensus and
a final version of the Arabic LANSS produced.
It is worth noting that the original developers of
the LANSS were not involved in initial translation as
they were not Arabic speakers. However, the back
translation was compared to the original by members
of the team who originally developed the Arabic ver-
sion of the S-LANSS.
2.2. Testing reliability and linguistic validity of
the Arabic S-LANSS
The sample size needed to detect a statistically signifi-
cant correlation between the scores of the LANSS and
the S-LANSS was calculated based on the assumption
that a probability is 95 percent that the study will
detect a relationship between Score of the S-LANNS
and the Score of the LANSS at a two-sided 0.05 sig-
nificance level. This calculation suggested that 100
participants would be required so a target of 110 par-
ticipants was set to account for 10% attrition. It was
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also estimated that this sample size would be sufficient
for calculating the internal consistency of the LANSS
items using Cronbach’s alpha.
2.3. Recruitment and selection of sample
Eligibility criteria for inclusion in the study were adults
(≥ 18 years) who had a formal diagnosis of diabetes
which has been present for at least five years.
Individuals were excluded if they were: a hospital in-
patient; had pre-existing comorbidities such as cancer,
shingles or other neuropathic pain entity that pre-
dated diabetes or can mimic or cause a neuropathic
pain that is not arising as a result of diabetes; were
pregnant as diabetes may be of gestational type; had
recently experienced physical trauma that may have
contributed to neuropathic pain; and had trauma or
dermatological diseases of the skin as this could affect
skin sensitivity (e.g. wound, psoriasis and eczema).
2.4. Study procedures
The study was advertised by posters and by word of
mouth at the Benghazi Diabetes Centre. Interested
volunteers received a participant information sheet
and a self-screening eligibility form and were asked
to contact the Principal Investigator (SG) no sooner
than 48 h if they wished to volunteer to participate in
the study, which consisted of two visits to the clinic.
During study visit 1, participants were briefed
about the study, screened for eligibility and enrolled
onto the study by signing a consent form.
Demographic data, such as age, weight and height,
were also collected to describe the sample.
Participants completed the Arabic LANSS and the
Principal Investigator undertook the clinical examina-
tion for tactile allodynia and pinprick threshold by
touching painful and adjacent non-painful areas with
a cotton wisp and a syringe needle, respectively.
Participants then completed the Arabic S-LANSS. A
nurse assisted participants with reading difficulties.
Participants returned for study visit 2 after 7–14 d
and completed the Arabic LANSS questionnaire.
Participants were also required to report other symp-
toms and complications associated with diabetes.
2.5. Data analysis
The data were analysed using SPSS 22. Concurrent
validity was tested by comparing Arabic LANSS scores
from study visit 1 and 2 with the Arabic S-LANSS
score. The inter-class correlation coefficient (ICC) was
calculated for total score of the two questionnaires
(LANSS visit 1 and 2). Test-retest reliability of the
Arabic LANSS was tested by calculating the ICC of all
items and comparing the total score for the two study
visits. Cronbach’s alpha was calculated for the Arabic
LANSS using data gathered from the two study visits.
It is worth noting that the inter-class correlation
was used to determine agreement between total
scores of the Arabic S-LANSS versus the Arabic
LANSS in visit 1 and also between the two visits of
the Arabic LANSS because the possible total score,
which is based on a numerical value given to Yes or
No answers to the questions, ranged from 0 to 24 and
therefore is treated as continuous. However, Cohen
Kappa was used to check the agreement between the
different items as the answers to these questions are
binomial (Yes or No).
3. Results
3.1. Translation of the LANSS to Arabic
There were no major issues arising during the transla-
tion process. The final version of the Arabic LANSS is
presented in Figure 1.
3.2. Reliability and linguistic validity of The
Arabic LANSS
One hundred and ten participants enrolled and all
completed the study (age = 19–82 years, Body Mass
Index = 18.81–40.74 kgm2, 55 females). All partici-
pants reported that they understood questions in
the Arabic LANSS and Arabic S-LANSS and there
were no instances of participants raising issues
about ambiguous words. Questions from the LANSS
and the S-LANSS were read verbatim to participants
who had difficulties with reading and/or writing
(Table 1.) Data from one male participant were
removed from analysis because they disclosed at the
end of the study that they were diagnosed with dia-
betes within five years but did not disclose this at
screening because he wanted to take part in the
study. Data were missing for height and for weight
for four male and one female and plasma glucose
data for five males and one female. These were pro-
cessed as missing data in subsequent analysis.
Anthropometric and demographic data are pre-
sented in Table 1. Mean ± SD plasma glucose con-
centration was 158.38 ± 57.42 mg/dl (n = 103
participants). Mean ± SD duration of diabetes was
15.28 ± 10.06 years (n = 109) and females had experi-
enced diabetes for a longer duration than males. This
difference did not appear to be related to age as there
were no statistically significant differences in age
between female and male participants (p > 0.05).
Twenty-eight (51.9%) males reported that they were
smokers (mean ± SD duration = 11.41 ± 13.34 years),
but none of the females reported being a smoker.
Twenty-nine males (53.7%) reported that they were
employed compared with 23 females (41.8%,
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p = 0.21). Forty-five participants scored ≥ 12 points on
the Arabic LANSS at study visit 1 and 45 participants
scored ≥ 12 points on study visit 2. Forty-five partici-
pants scored ≥ 12 points on the Arabic S-LANSS at
study visit 1. Hence, point prevalence of peripheral
diabetic neuropathy was calculated as 41.3% (95%
Confidence Intervals = 32.55–50.7%).
Participants in the sample presented with a variety
of complications associated with diabetes including
eye problems (e.g. cataract n = 28, 25.7%), erectile
dysfunction (n = 14, 12.8%), joint stiffness (n = 9,
8.3%). Participants in the sample presented with a
variety of comorbidities such as hypertension
(n = 31, 28.4%), heart diseases (n = 20, 18.3%), thyroid
gland disorders (n = 17, 15.6%), arthritis (n = 6, 5.5%),
asthma (n = 2), kidney disease (n = 1), hepatitis (n = 1)
and hyperlipidaemia (n = 1). Only eight (7.3%) parti-
cipants reported that they had been diagnosed with
peripheral diabetic neuropathy.
3.3. Internal consistency
Cronbach’s alpha values suggested acceptable inter-
nal consistency for Arabic LANSS scores at study visit
1 (0.793) and this was similar to that for Arabic
S-LANSS scores (0.796). Cronbach’s alpha suggested
Table 1. Mean + SD or tallies of anthropometric and demographic data of participants.
Characteristic
Men
(n = 54)
Women
(n = 55)
All sample
(n = 109) P valuea
Age (years) 48.09 ± 14.84 51.62 ± 14.00 49.87 ± 14.47 0.21
BMI (kg/m2) 28.43 ± 4.87 29.14 ± 4.89 28.80 ± 4.87 0.46
Plasma glucose (mg/dl) 154.08 ± 59.20 162.28 ± 56.02 158.38 ± 57.42 0.47
Duration of diabetes (years) 12.56 ± 7.12 17.95 ± 11.74 15.28 ± 10.06 0.05
Smoking (%) n = 28 (51.9%) n = 0 (0%) 25.7% 0.00
Duration of smoking (years) 11.41 ± 13.34 b 11.41 ± 13.34b 0.00
Employment (%) n = 29 (53.7%) n = 23 (41.8%) n = 52 (47.7%) 0.21
Education (%)
● Cannot read or write n = 9 (16.7%) n = 15 (27.3%) n = 24 (22.0%) 0.18
● Can read and write n = 7 (13.0%) n = 8 (14.5%) n = 15 (13.8%) 0.82
● Primary n = 8 (14.8%) n = 9 (16.4%) n = 17 (15.6%) 0.81
● Secondary n = 17 (31.5%) n = 10 (18.2%) n = 27 (24.8%) 0.11
● University or above n = 13 (24.1%) n = 13 (23.6%) n = 26 (23.9%) 0.95
Marital status (%)
● Married (no children) n = 6 (11.1%) n = 0 (0%) n = 6 (5.5%) 0.01
● Married (with children) n = 40 (74.1%) n = 51 (92.7%) n = 91 (83.5%) 0.00
● Unmarried n = 8 (14.8%) n = 4 (7.3%) n = 12 (11.0%) 0.00
aDifferences between mean ± SD of men and women were tested by unpaired t-test, while differences between proportions of males and females in
other parameters were tested by Z-test.
bNone of the women were smokers, so there is no mean or standard deviation for this group. In all sample these figures are only for males.
Figure 1. The Final version of the Arabic Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
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acceptable internal consistency for Arabic LANSS
scores between study visit 1 and 2 (0.795).
3.4. Concurrent validity
Inter-class correlation values between Arabic LANSS
total scores and Arabic S-LANSS total scores at study
visit 1 suggested acceptable concurrent validity.
Kappa measurement of agreement between Arabic
LANSS and S-LANSS scores at study visit 1 was very
high for all seven items (Table 2).
3.5. Test-retest reliability
Inter-class correlation between Arabic LANSS total
scores at study visit 1 and 2 was 0.999 (p < 0.001) sug-
gesting acceptable test-retest reliability. Kappa mea-
surement of agreement was high for all items of the
Arabic LANSS between studies visit 1 and 2 (Table 2).
4. Discussion
To our knowledge, this is the first report of the trans-
lation and cultural adaptation of the LANSS pain scale
into Arabic. We used an Arabic S-LANSS pain scale
that had been culturally adapted for use in Libya [9]
to test concurrent validity of the Arabic LANSS pain
scale. The Arabic LANSS had high test-retest reliability
and data suggested that it was linguistically valid and
culturally suitable for use on people with diabetes in
Benghazi, Libya. It was easy to complete, suggesting
that translated versions of the LANSS pain scale have
clinical utility in ethno-culturally diverse populations.
We decided to translate the LANSS pain scale because
the sensitivities and specificities of different languages of
the LANSS are higher than 80% [1]. The Turkish LANSS
has a sensitivity of 89.9% and a specificity 94.2%, and a
positive predictive value of 93.6% and a negative pre-
dictive value of 90.7% [10]. The Spanish LANSS has good
reliability with Cronbach and Guttman split-half coeffi-
cients between 0.68 and 0.71 and a kappa coefficient for
inter-rater agreement of 0.70 and intra-class correlation
coefficients between 0.77 and 0.92. Specificity is 89.4%
and positive predictive value is 91.1%. Validity is good
with a kappa coefficient of 0.70 (CI 95% 0.59–0.81;
p < 0.0001) and area under the curve 0.929 (p < 0.0001)
[12]. Cultural validation in China was highly reliable with
Cronbach’s alpha coefficients and Guttman half coeffi-
cients for internal consistency being 0.824 and 0.842,
respectively. It has good face validity and high content
validity with sensitivity being 80.0% and specificity
97.1%, and a positive predictive value of 96.9% and
negative predictive value of 82.9% [13]. Moreover, the
Neuropathic Pain Questionnaire (NPQ) has the lowest
reported accuracy of other available tools and the DN4
may not preserve its diagnostic accuracy in specific
patient populations such as acute postoperative pain
patients. PainDETECT had lower sensitivity and specificity
when tested on other pain groups than the originally
validated and the ID-Pain is relatively sensitive but not
specific in specific pain groups such as patients with
breast cancer. The Standardized Evaluation of Pain
(StEP) is copyrighted and has only been validated in a
lower back pain group [1].
Our study is the first to provide initial data
related to the point prevalence of painful diabetic
neuropathy in Libya. We found that 41.3% of parti-
cipants, in this small sample, diagnosed with dia-
betes that has persisted for at least five years
presented with painful diabetic neuropathy. This
estimate is of similar magnitude to previous reports
on larger samples from populations in the Middle
East. For example, Jambart et al. [22] estimated the
point prevalence of painful diabetic neuropathy to
be 53.7% in a population of 4097 from five different
MENA countries. However, our estimate is prelimin-
ary and based on a study designed to translate the
LANSS into Arabic. The small sample size of partici-
pants recruited from a single clinic from one city
means that the estimate should be treated with
caution. A large multi-site epidemiological study is
needed. Our study found that plasma glucose levels
were higher than normal ranges for patients with
diabetes, especially in patients with possible painful
diabetic neuropathy. This might support the theory
that painful diabetic neuropathy is more common in
patients with poorly controlled diabetes [23]. Our
finding that none of the female participants
reported being smokers is consistent with data
from the Tobacco Atlas that only 0.9% of females
aged >15 years in Libya are daily smokers [24].
4.1. Strengths and limitation of the study
The findings of our study have clinical implications,
especially for healthcare professionals working in dia-
betes clinics. Small modifications of service delivery in
diabetes clinics could improve the detection and
management of painful diabetic neuropathy in
patients with diabetes. Clinicians should be mindful
of patients reporting pain and/or sensory
Table 2. Kappa measurement of agreement between Arabic
LANSS and Arabic S-LANSS scores at study visit one and for
Arabic LANSS between study visit 1 and 2.
Arabic LANSS (visit 1)
vs
Arabic S-LANSS (visit 1)
Arabic LANSS visit 1
vs
Arabic LANSS visit 2
Kappa P value Kappa P value
Item 1 0.98 <0.01 1 <0.001
Item 2 1 <0.001 1 <0.001
Item 3 1 <0.001 1 <0.001
Item 4 0.98 <0.01 0.98 <0.01
Item 5 0.95 <0.01 1 <0.001
Item 6 1 <0.001 1 <0.001
Item 7 0.97 <0.01 1 <0.001
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disturbances in the previous six months. In Libya and
the MENA region the Arabic LANSS or the S-LANSS,
which can be completed within minutes can be used
in service delivery to detect the presence of painful
diabetic neuropathy. This information can then be
used to inform health care professionals about the
most appropriate pharmacological strategy to adopt.
However, our findings on the initial prevalence of
neuropathic pain should be approached with caution
as the sample is not very representative and is very
small. In addition, the intention of the study was to
test the validity and reliability of the Arabic LANSS
and not to provide epidemiological figures. Another
major limitation of this study is that there was no gold
standard method to test the sensitivity and specificity
of the Arabic LANSS such as detailed case history,
clinical examination and further investigations if
needed; this was not feasible as the time-frame for
the study and resources were limited. Moreover, the
testing of concurrent validity of the LANSS by com-
parison with the similar S-LANSS completed at the
same time is a drawback.
4.2. Conclusion
The Arabic LANSS pain scale developed in this study
was valid and reliable for use in Libya for people
diagnosed with diabetes. This study provided data
suggesting that the S-LANSS could also be used in
this population. However, the use of the S-LANNS in
a postal survey is limited to patients with reading
difficulties. We plan to use the Arabic LANSS or S-
LANSS in an epidemiological study to estimate the
point prevalence of painful diabetic neuropathy in
Libya.
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